sibeprenlimab-szsi (Voyxact)

Introduction

Inducations:

• treatment of proteinuria in patients with IgA nephropathy

Dosage

• 200 MG/ML Prefilled Syringe (2 mL) [Voyxact]

Adverse effects

• upper respiratory tract infections
• injection site reactions
• immunosuppression

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• humanized monoclonal antibody
  • inhibits APRIL (CD256), a protein that promotes the production of the abnormal IgA antibodies implicated in IgA nephropathy, thus reducing kidney damage

More general terms

• pharmaceutical monoclonal antibody